Resume_2016
- 1. Rakesh K Singh, Ph.D. 2505 Crestline Circle, Lawrence, KS 66047 7 85-840-0212 | rakeshlumc@gmail.com PROFI LE Neuropharmacologist with over 8years of multi-disciplinary research and communication experience in academia and industry. Published 8high impact articles in the areas of neuroscience, pharmacology, and rheumatology. Uniquely qualified to compile, organize, write, edit, and produce a wide range of medical and scientific documentation required to support product development efforts. Possess unique combination of laboratory skills in pharmacology and human disease, proficient in analysis and presentation of basic and clinical science, and experience in publication planning and strategic development of pharmaceutical therapies. Experienced in publication management and planning, conducting gap analyses, literature searches, and writing various medical communications, consumer, and sales rep training and detailing materials. Managed delivery of the scientific content of medical communications, strategic consultancy to clients based upon scientific expertise, and reviewed scientific content for range of medical communications. Led communications business unit team to drive business to meet/exceed client expectations by providing scientific leadership in specific therapeutic categories. EDUCAT I ON University of Kansas Lawrence, KS Doctor of Philosophy (PhD) 2008 Dissertation project: Novel role of JAK-STAT pathway in mediating the effects of atypical antipsychotics on serotonin 2A receptor signaling: Advisor: Nancy A. Muma, Ph.D. Investigated potential effects of atypical antipsychotics on 5-HT2A receptors and associated proteins like Regulators of G protein Signaling proteins (RGS) both in cells and in animals. Findings resulted in three first author publication with a total of six publications in reputed journals. Birla Institute of Technology Ranchi, India Bachelor of Pharmaceutical Sciences (B.Pharmacy) 1999 Coursework and laboratory training in Pharmacology and Toxicology, Medicinal Chemistry, Pharmaceutics, Pharmacokinetics and Pharmacotherapy, Pharmaceutical Chemistry.
- 2. EXPERI ENCE University of Kansas Kansas City, KS Senior Scientist 2015 present Design and perform experiments to understand Pharmacological interaction of Methotrexate and NAMPT protein activity Prepare abstracts, presentations, and manuscripts Develop study proposals Grant writing and submission Ensure compliance with regulatory guidelines RxPrism Health Systems Bangalore, India Associate Medical Director 2014 2015 Medical writing leadership to develop high-quality & medically accurate deliverables Serve as the main client contact for project development, presentations and client discussions Ensure project development according to medical writing standard operating procedures and client standards were done on time and on budget Coordinate editorial process flow, timelines, third-party vendors, and communications with sponsors to produce timely deliveries Midwest Biomedical Research Foundation Kansas City, MO Clinical Research Coordinator 2012 2014 Responsible for study administration, protocol preparation, subject visits, documentation, and subject enrollment Preparing informed consent documents, case report forms, enrollment and drug/device accountability documents Planning, designing, documentation, and conducting basic science research to enhance understanding of substance abuse and changes in enzymatic activity in Alzheimers disease and in elderly Indigene Lifesystems Ltd Bangalore, India Associate Manager-Medical Writing 2011 2014 Responsible for end to end content requirements of the projects, client service and team management Training support and resource development Strategy for new business and services
- 3. University of Illinois at Chicago Chicago, IL Research Associate 2008 2011 Design and perform experiments to understand role of membrane biology in therapeutic lag time with antidepressant treatment Prepare abstracts, presentations, and manuscripts Develop study proposals Grant writing and submission Ensure compliance with regulatory guidelines Laboratory upkeep and maintenance Supervising student researchers PUBLI CAT IONS 1. Funk RS, Singh R,, Pramann L, Gigliotti N, Islam S, Heruth DP, Ye SQ, ChanMA, Leeder JS, Becker ML: Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro. Clinical and Translational Science; 11 MAY 2016 2. Rakesh K. Singh, Ariana A. Khosravani, Jeffrey L. Benovic and Mark.M. Rasenick: Activation of GRK2 causes tubulin phosphorylation and subsequent increases in Gs alpha activity, manuscript in preparation, 2012. 3. Rakesh K. Singh, Jia C, Garcia F, Carrasco GA, Battaglia G, Nancy A. Muma. (2009) Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release. J of Psychopharmacology March; 2009. 4. Rakesh K. Singh, Jeff L. Staudinger, and Nancy A. Muma. (2008) Activation of the JAK- STAT pathway is necessary for desensitization of 5-HT2A receptor signaling by atypical antipsychotic drugs The International Journal of Neuropsychopharmacology Cambridge University Press; 2008 Oct 31:1-15. 5. Shi J, Damjanoska KJ, Singh RK, Carrasco GA, Garcia F, Grippo AJ, Landry M, Sullivan NR, Battaglia G, Muma NA. (2007) Agonist induced-phosphorylation of Galpha11 protein reduces coupling to 5-HT2A receptors. J Pharmacol Exp Ther Oct; 323(1):248-56. 6. Muma NA, Singh RK, Vercillo MS, D'Souza DN, Zemaitaitis B, Garcia F, Damjanoska KJ, Zhang Y, Battaglia G, Vande Kar LD. Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex. (2007) Neuropharmacology. Sep; 53(4):552-62. 7. Singh RK, Shi J, Zemaitaitis BW, Muma NA. (2007) Olanzapine Increases RGS7 Protein Expression via Stimulation of the JAK-STAT Signaling Cascade. J Pharmacol Exp Ther Jul; 322(1):133-40.
- 4. 8. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. (2006). The tumor suppressor PTEN is necessary for human sprouty 2 mediated inhibition of cell proliferation. J Biol Chem Feb 24; 281(8): 4816-22. 9. Francis Edwin, Gregory J. Wiepz, Rakesh Singh, Chimera R. Pete, Deepti Chaturvedi, Paul J. Bertics and Tarun B. Patel (2005). A Historical Perspective of EGFR and Related Systems in Epidermal Growth Factor, Methods and Protocols, Methods in Molecular Biology Humana Press, Vol. 327, Page. 224. SELECT ED PRESENT AT I ON 1. Evaluation of the Relationship between Methotrexate Polyglutamation and Efficacy in the Collagen-induced Arthritis Mouse Model. Abstract submitted for 2016 annual meeting of The American College of Rheumatology (ACT), Washington, DC. 2. Hydroxychloroquine Inhibits the Cellular Catabolism of HumanImmunoglobulin. Poster presentation at the 2016 annual meeting of The American Society for Clinical Pharmacology and Therapeutics (ASCPT), San Diego, CA. 3. GRK2 Phosphorylates tubulin in PC12 cells Lipid Rafts-Implication for Neuronal G-Protein signaling. Poster presentation at the 2010 annual research symposium of the College of Medicine at UIC, Chicago, IL. 4. GPCR activation causes phosphorylation of tubulin in PC-12 cell lipid raft: implications for neuronal G protein signaling. Poster presentation at the 2009 annual meeting of the Society of Neuroscience, Chicago, IL. 5. Atypical antipsychotics induce desensitization of 5-HT2A receptor signaling-Role of JAK- STAT cascade. Poster presentation at the 2007 annual meeting of the Society of Neuroscience, San Diego, CA. 6. Antagonist mediated desensitization of 5-HT2A receptor signaling. Poster presentation at the 2006 annual meeting of the Society of Neuroscience, Atlanta, GA. REFERENCES Ryan S. Funk, Pharm.D., Ph.D. Assistant Professor of Pharmacy Practice University of Kansas Medical Center 3901 Rainbow Blvd, MS 4047, 6013 Wescoe Kansas City, KS 66160 Phone: 913-945-6904 E-mail: ryanfunk@kumc.edu Nancy A. Muma, Ph.D. Professor and Chair Department of Pharmacology and Toxicology The University of Kansas
- 5. Malott Hall Room 5064B 1251 Wescoe Hall Drive Lawrence, KS 66407 Phone: 785-864-4002 E-mail: nmuma@ku.edu Mark M. Rasenick, Ph.D. Distinguished UIC Professor Department of Physiology and Biophysics, and Psychiatry Director, Biomedical Neuroscience Training Program College of Medicine University of Illinois at Chicago 835 S. Wolcott Ave., (M/C 901) Chicago, IL 60612-7342 Phone: 785-864-2626 E-mail: raz@uic.edu William Suo, MD Director, Lab For Alzheimers Disease & Aging Research Kansas City Veterans Affairs Medical Center Research Scientist and Associate Professor Departments of Neurology and Physiology University of Kansas Medical Center 4801 E. Linwood Blvd. Kansas City, MO 64128 Phone: 816-861-4700X57084 Email: william.suo@va.gov , zsuo@kumc.edu